Monk Recaps Benefit of Rucaparib Maintenance Therapy in Advanced Ovarian Cancer
July 18th 2022Dr Monk discusses pertinent efficacy and safety data from the ATHENA-MONO trial, which evaluated first-line maintenance treatment with rucaparib in patients with stage III-IV high-grade ovarian cancer.
Read More
Spiess Shares the Importance of Comprehensive, Multidisciplinary Care in Penile Cancer
July 11th 2022Dr Spiess talks about taking part in an international consortium that seeks to establish a standard treatment for penile cancer, the ways shame interferes with diagnosis and treatment, and the complicated issues of gender and sexuality involved with this disease.
Read More
Duma Discusses the Unique Challenges of Women With Lung Cancer (Continued)
July 4th 2022Dr Duma discusses improving diversity in trials and in oncology providers, how the oncology field fails women in general and women of color in particular, and the stress lung cancer puts on a woman’s home life.
Read More
Investigators Explore RARA Overexpression With Tamibarotene in Higher-Risk MDS
June 28th 2022Risk stratification for patients with myelodysplastic syndrome have afforded those with asymptomatic or low-risk disease treatment pathways that can be navigated using a variety of patient characteristics. However, treatment algorithms for patients with higher-risk disease are limited to allogeneic transplant or treatment with hypomethylating agents.
Read More
Leukemia Pioneers Chronicle Career Experiences and Milestones
June 27th 2022Drs Karp, Raza, and Le Beau discuss challenges they faced in their early careers as women in leukemia, the ways they overcame those obstacles, and the unique pitfalls and successes they’ve experienced as female physicians.
Read More
Wise Summarizes Survival Data From ARASENS and PEACE-1 in Prostate Cancer
June 20th 2022Dr. Wise highlights how intensified treatment with doublet or triplet therapy can lead to better long-term outcomes in prostate cancer, potential treatment sequencing options, and the importance of communication between patients and physicians.
Read More
Lee Lays Out Treatment Developments in Non–Clear Cell RCC
June 16th 2022Dr Lee highlights treatment developments in non–clear cell renal cell carcinoma, emphasizes the need for precise classification of the histologic subsets of this disease, and discusses the investigation of cabozantinib plus nivolumab across stratified cohorts of non–clear cell renal cell carcinoma.
Read More
Ueno Underscores the Importance of Accurate Diagnoses and Novel Treatments in IBC
June 13th 2022Dr Ueno discusses the challenges of diagnosing inflammatory breast cancer, the unmet need for new agents to treat patients with the disease, and the current ongoing research he’s eager to see reported.
Read More
Jefferson Faculty Highlight COVID-19-Induced Disparities in Older Patients With Cancer
June 6th 2022Chapman, Swartz, Rhodes, Nightingale, and Denton highlight the evolution of Jefferson Health’s Senior Adult Oncology Center, the unique needs of older adults who develop cancer, and challenges stemming from the COVID-19 pandemic that have affected the care of geriatric patients with cancer, such as the strain put on caregivers and the shift to telemedicine.
Read More
Dr Abid discusses a review paper, published in Cancer Cell, that evaluated determinants of response to SARS-CoV-2 vaccines in patients who underwent allogeneic or autologous hematopoietic cell transplantation or who had received CAR T-cell therapy or bispecific T-cell engagers.
Read More
Karmanos Faculty Share Experiences and Career Insights as Women in Oncology
May 30th 2022Drs Mamdani, Assad, and Robinette discuss the changes in the culture of oncology today compared with when they first started their careers, the challenges they experienced along the way, and advice they would share with up-and-coming oncologists based on what they know now.
Read More
Tarantino Previews Exciting Research in HER2-Low Breast Cancer
May 26th 2022Dr Tarantino provides background on the categorization of HER2-low disease in breast cancer, issues with standardization and interpretation, historical management strategies, and ongoing research with agents including trastuzumab deruxtecan, trastuzumab duocarmazine, and disitamab vedotin.
Read More
Taylor Provides Insight Into Pirtobrutinib Resistance in CLL
May 23rd 2022Dr Taylor discusses the significance of BTK inhibition in chronic lymphocytic leukemia, describes the key objectives of, and methods used, for the genomic analyses performed by his team, underscores the clinical significance of the data yielded from this research, and outlines where future efforts will focus.
Read More
Pro Presents Interim Results of PRIMO in Peripheral T-Cell Lymphoma
May 19th 2022Dr Pro outlines the current role of duvelisib in peripheral T-cell lymphoma (PTCL), reviews some key adverse effects associated with the agent, and walks us through other important updates in PTCL presented at the 2021 ASH Annual Meeting and Exposition.
Read More
Pal Discusses Eye-Catching ASCO GU Data in RCC
May 16th 2022Dr Pal walks us through research presented at the 2022 Genitourinary Cancers Symposium, including data from the TIVO-3 trial (NCT02627963) and findings from the NeoAvAx trial (NCT03341845) exploring avelumab plus axitinib for patients with high-risk, nonmetastatic clear-cell renal cell carcinoma.
Read More
Pegram Expounds on Exciting Developments in HER2+ Metastatic Breast Cancer
May 12th 2022Dr Pegram discusses approaches to treatment sequencing in HER2-positive metastatic breast cancer, the influence of the DESTINY-Breast03 trial (NCT03529110) on the breast cancer treatment paradigm, and ongoing research in the field.
Read More
Cusnir on the Benefits of SIR-Spheres® Y-90 Resin Microspheres in mCRC
May 9th 2022Dr Cusnir reviews the benefits of isolating the liver in early colorectal cancer (CRC) treatment, how patients have tolerated Y-90 therapy, and situations in which Y-90 therapy would be most effective for patients with CRC.
Read More
Borgen Recommends Revamping Peer Review for a Post-COVID-19 World
May 5th 2022Dr Borgen recaps a presentation he made at the 2022 Miami Breast Cancer Conference highlighting the flaws with preprints, outlining his recommendations for fixing peer review, and explaining how this affects cancer research.
Read More
FDA Approval Insights: Relatlimab Plus Nivolumab in Melanoma
May 2nd 2022Dr Lipson discusses the significance of the regulatory decision for relatlimab and nivolumab, updated data from the RELATIVITY-047 trial, adverse effects clinicians associated with the doublet, and the potential next steps for this therapy in melanoma.
Read More
Trimodality Approach to MIBC Paves Path for Bladder Preservation
April 20th 2022Standard chemoradiation therapy regimens have had marked success for patients with muscle-invasive bladder cancer; however, up to 30% of patients who receive treatment with bladder preserving intent will have recurrence.
Read More
D'Abreo Addresses AEs in Metastatic Breast Cancer Care
April 14th 2022Dr D’Abreo discusses adverse effects that are common in metastatic breast cancer, shares advice on establishing an open channel of communication with patients, and highlights preventive and proactive management strategies for treatment-related adverse effects.
Read More